Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.1172 | 1 | 1 |
Echinococcus granulosus | endo beta n-acetylglucosaminidase | 0.0084 | 0.0378 | 0.0378 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.1172 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.1172 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase | 0.1172 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1172 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0102 | 0.054 | 0.0229 |
Giardia lamblia | Kinase, CMGC MAPK | 0.1172 | 1 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.1172 | 1 | 1 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0102 | 0.054 | 0.054 |
Trichomonas vaginalis | beta-glucosidase, putative | 0.0099 | 0.0516 | 0.0182 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1172 | 1 | 1 |
Brugia malayi | Glycosyl hydrolase family 85 protein | 0.0084 | 0.0378 | 0.0378 |
Echinococcus granulosus | geminin | 0.0077 | 0.0319 | 0.0319 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1172 | 1 | 1 |
Schistosoma mansoni | endo beta n-acetylglucosaminidase | 0.0084 | 0.0378 | 0.0061 |
Schistosoma mansoni | alpha-glucosidase | 0.0114 | 0.0643 | 0.0335 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1172 | 1 | 1 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0132 | 0.0806 | 0.0806 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1172 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.1172 | 1 | 1 |
Schistosoma mansoni | alpha-l-fucosidase | 0.0181 | 0.124 | 0.0952 |
Trypanosoma brucei | protein kinase, putative | 0.1172 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.1172 | 1 | 1 |
Schistosoma mansoni | alpha-glucosidase | 0.0114 | 0.0643 | 0.0335 |
Echinococcus multilocularis | geminin | 0.0077 | 0.0319 | 0.0319 |
Mycobacterium ulcerans | alpha-L-fucosidase | 0.03 | 0.2289 | 0.5 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0102 | 0.054 | 0.054 |
Schistosoma mansoni | thyroid hormone receptor | 0.011 | 0.0613 | 0.0304 |
Trichomonas vaginalis | glycoside hydrolases, putative | 0.0099 | 0.0516 | 0.0182 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0132 | 0.0806 | 0.0445 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.1172 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.1172 | 1 | 1 |
Onchocerca volvulus | 0.0076 | 0.0313 | 0.5 | |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.0181 | 0.124 | 0.0896 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1172 | 1 | 1 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0132 | 0.0806 | 0.0806 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.1172 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.1172 | 1 | 1 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 0.03 | 0.2289 | 0.2289 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.011 | 0.0613 | 0.0613 |
Echinococcus granulosus | fucosidase alpha L 1 tissue | 0.03 | 0.2289 | 0.2289 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0132 | 0.0806 | 0.0806 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0132 | 0.0806 | 0.0806 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.1172 | 1 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.011 | 0.0613 | 0.0304 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.0181 | 0.124 | 0.124 |
Echinococcus multilocularis | endo beta n-acetylglucosaminidase | 0.0084 | 0.0378 | 0.0378 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.